{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:21:50Z","timestamp":1793413310002,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis is a rare autoimmune disease mediated by autoantibodies directed against acetylcholine receptors (AChRs) at the neuromuscular junction. These autoantibodies cause dysfunction through AChR blockade, AChR degradation due to crosslinking and internalisation, and complement activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A novel in vitro model of the human neuromuscular junction was established on a microfluidic platform to investigate the effect of anti-AChR autoantibodies on complement activation and neuromuscular transmission and the mechanism of action of complement inhibition in myasthenia gravis. The NeuroMuscle\n                      <jats:sup>TM<\/jats:sup>\n                      platform enabled the connection of human induced pluripotent stem-cell-derived motor neuron spheroids with three-dimensional cultures of skeletal muscle fibres, forming functional neuromuscular junctions. Functional connectivity was assessed by glutamate stimulation of motor neuron spheroids and monitoring of calcium transients in genetically encoded calcium indicator protein 6 (GCaMP6)-transduced muscle fibres.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Incubation of in vitro neuromuscular junction tissues with sera from patients with anti-AChR autoantibody-positive myasthenia gravis, in contrast to healthy controls, induced a significant increase in membrane attack complex (MAC) deposition and complement split products, accompanied by a notable reduction in calcium transients. Treatment with zilucoplan, a complement component 5 (C5) inhibitor, prevented complement activation and preserved neuromuscular junction functional integrity. The model demonstrated that complement-mediated damage is a major driver of neuromuscular junction functional impairment in the myasthenia gravis patient sera tested in this study. Furthermore, the study explored the reversibility of neuromuscular junction damage, revealing that shortening the delay before initiating complement inhibitor treatment in the in vitro neuromuscular junction tissues enhances the reversibility of neuromuscular transmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings offer a mechanistic rationale for the observed clinical response in patients with anti-AChR autoantibody-positive myasthenia gravis treated with C5 inhibitors. The in vitro neuromuscular junction model provides a robust platform for studying the mechanistic pathways of complement-mediated damage and evaluating therapeutic interventions for myasthenia gravis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-025-01056-1","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T17:06:24Z","timestamp":1765559184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Human in vitro neuromuscular junction model to functionally dissect the pathogenic mechanism of anti-AChR autoantibody-positive myasthenia gravis"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9892-5279","authenticated-orcid":false,"given":"Baehyun","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret H.","family":"Magdesian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camil E.","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Ekert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douangsone D.","family":"Vadysirisack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"2","key":"1056_CR1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/ijms19020490","volume":"19","author":"SJ Burden","year":"2018","unstructured":"Burden SJ, et al. Fundamental molecules and mechanisms for forming and maintaining neuromuscular synapses. Int J Mol Sci. 2018;19(2):490.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1056_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475\u201390.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1056_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"key":"1056_CR4","doi-asserted-by":"crossref","unstructured":"Petersson M, et al. Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG study. Neurology. 2021;97(14):e1382\u2013e1391.","DOI":"10.1212\/WNL.0000000000012604"},{"issue":"7","key":"1056_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","volume":"18","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022;18(7):691\u2013701.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"1056_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr","year":"2018","unstructured":"Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113\u201328.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"1056_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society. J Neurol. 2016;263(8):1473\u201394.","journal-title":"J Neurol"},{"issue":"5","key":"1056_CR8","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/mus.27973","volume":"68","author":"Y Ozawa","year":"2023","unstructured":"Ozawa Y, et al. Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies. Muscle Nerve. 2023;68(5):798\u2013804.","journal-title":"Muscle Nerve"},{"key":"1056_CR9","doi-asserted-by":"publisher","first-page":"109551","DOI":"10.1016\/j.jneumeth.2022.109551","volume":"373","author":"JJ Plomp","year":"2022","unstructured":"Plomp JJ, et al. A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies. J Neurosci Methods. 2022;373:109551.","journal-title":"J Neurosci Methods"},{"issue":"3","key":"1056_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ana.410430315","volume":"43","author":"RL Ruff","year":"1998","unstructured":"Ruff RL, Lennon VA. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann Neurol. 1998;43(3):370\u201379.","journal-title":"Ann Neurol"},{"issue":"2","key":"1056_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham MC, et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 2023;146(2):319\u201336.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"1056_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","volume":"39","author":"K Sahashi","year":"1980","unstructured":"Sahashi K, et al. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol. 1980;39(2):160\u201372.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"1056_CR13","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):EVIDoa2100066.","journal-title":"NEJM Evid"},{"issue":"5","key":"1056_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395\u2013406.","journal-title":"Lancet Neurol"},{"key":"1056_CR15","doi-asserted-by":"publisher","first-page":"175628642412431","DOI":"10.1177\/17562864241243186","volume":"17","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, et al. Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Ther Adv Neurol Disord. 2024;17:17562864241243186.","journal-title":"Ther Adv Neurol Disord"},{"key":"1056_CR16","doi-asserted-by":"publisher","first-page":"1213920","DOI":"10.3389\/fimmu.2023.1213920","volume":"14","author":"G-Q Tang","year":"2023","unstructured":"Tang G-Q, et al. Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. Front Immunol. 2023;14:1213920.","journal-title":"Front Immunol"},{"issue":"5","key":"1056_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383\u201394.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1056_CR18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1056_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1091\/mbc.e13-11-0670","volume":"25","author":"J Rosenblatt","year":"2014","unstructured":"Rosenblatt J, Gartner Z. Cells: shaping tissues and organs. Mol Biol Cell. 2014;25(6):730.","journal-title":"Mol Biol Cell"},{"issue":"3","key":"1056_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/17460441.2020.1700225","volume":"15","author":"OF Vila","year":"2020","unstructured":"Vila OF, et al. In vitro models of neuromuscular junctions and their potential for novel drug discovery and development. Expert Opin Drug Discov. 2020;15(3):307\u201317.","journal-title":"Expert Opin Drug Discov"},{"issue":"22","key":"1056_CR21","doi-asserted-by":"publisher","first-page":"dev193920","DOI":"10.1242\/dev.193920","volume":"147","author":"S Barbeau","year":"2020","unstructured":"Barbeau S, et al. Building neuromuscular junctions in vitro. Development. 2020;147(22):dev193920.","journal-title":"Development"},{"issue":"20","key":"1056_CR22","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/adhm.201600483","volume":"5","author":"YJ Choi","year":"2016","unstructured":"Choi YJ, et al. 3D cell printing of functional skeletal muscle constructs using skeletal muscle-derived bioink. Adv Healthc Mater. 2016;5(20):2636\u201345.","journal-title":"Adv Healthc Mater"},{"issue":"3","key":"1056_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.celrep.2018.03.091","volume":"23","author":"SM Maffioletti","year":"2018","unstructured":"Maffioletti SM, et al. Three-dimensional human iPSC-derived artificial skeletal muscles model muscular dystrophies and enable multilineage tissue engineering. Cell Rep. 2018;23(3):899\u2013908.","journal-title":"Cell Rep"},{"key":"1056_CR24","unstructured":"Protocol Exchange. Chemically defined differentiation of human pluripotent stem cells to hindbrain and spinal cord neural stem cells with defined regional identities. https:\/\/www.protocols.io\/view\/chemically-defined-differentiation-of-human-plurip-bp2l6d6xzvqe\/v1. Accessed July 2025."},{"issue":"10","key":"1056_CR25","doi-asserted-by":"publisher","first-page":"eaat 5847","DOI":"10.1126\/sciadv.aat5847","volume":"4","author":"T Osaki","year":"2018","unstructured":"Osaki T, et al. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Sci Adv. 2018;4(10):eaat5847.","journal-title":"Sci Adv"},{"issue":"3\u20134","key":"1056_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000443634","volume":"202","author":"AS Smith","year":"2016","unstructured":"Smith AS, et al. Creating interactions between tissue-engineered skeletal muscle and the peripheral nervous system. Cells Tissues Organs. 2016;202(3\u20134):143\u201358.","journal-title":"Cells Tissues Organs"},{"key":"1056_CR27","doi-asserted-by":"publisher","first-page":"e44530","DOI":"10.7554\/eLife.44530","volume":"8","author":"M Afshar Bakooshli","year":"2019","unstructured":"Afshar Bakooshli M, et al. A 3D culture model of innervated human skeletal muscle enables studies of the adult neuromuscular junction. Elife. 2019;8:e44530.","journal-title":"Elife"},{"issue":"5","key":"1056_CR28","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.7150\/thno.25735","volume":"9","author":"OF Vila","year":"2019","unstructured":"Vila OF, et al. Quantification of human neuromuscular function through optogenetics. Theranostics. 2019;9(5):1232\u201346.","journal-title":"Theranostics"},{"key":"1056_CR29","doi-asserted-by":"publisher","first-page":"745897","DOI":"10.3389\/fcell.2021.745897","volume":"9","author":"VM Smith","year":"2021","unstructured":"Smith VM, et al. A functional human-on-a-chip autoimmune disease model of myasthenia gravis for development of therapeutics. Front Cell Dev Biol. 2021;9:745897.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"1056_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.bpj.2012.07.003","volume":"103","author":"MH Magdesian","year":"2012","unstructured":"Magdesian MH, et al. Atomic force microscopy reveals important differences in axonal resistance to injury. Biophys J. 2012;103(3):405\u201314.","journal-title":"Biophys J"},{"issue":"2","key":"1056_CR31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1523\/JNEUROSCI.0906-12.2013","volume":"33","author":"MW Amoroso","year":"2013","unstructured":"Amoroso MW, et al. Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J Neurosci. 2013;33(2):574\u201386.","journal-title":"J Neurosci"},{"key":"1056_CR32","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3389\/fimmu.2019.02539","volume":"10","author":"M Mohebnasab","year":"2019","unstructured":"Mohebnasab M, et al. Current and future approaches for monitoring responses to anti-complement therapeutics. Front Immunol. 2019;10:2539.","journal-title":"Front Immunol"},{"issue":"5","key":"1056_CR33","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1007\/s00415-024-12209-3","volume":"271","author":"MD Weiss","year":"2024","unstructured":"Weiss MD, et al. Improvement of fatigue in generalised myasthenia gravis with zilucoplan. J Neurol. 2024;271(5):2758\u201367.","journal-title":"J Neurol"},{"issue":"2","key":"1056_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3949\/ccjm.90a.22017","volume":"90","author":"JA Morren","year":"2023","unstructured":"Morren JA, Li Y. Myasthenia gravis: frequently asked questions. Cleve Clin J Med. 2023;90(2):103\u201313.","journal-title":"Cleve Clin J Med"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01056-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:07:31Z","timestamp":1768849651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-025-01056-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01056-1","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Sera from myasthenia gravis patients were collected by BIOIVT with informed consent, adhering to the Department of Health and Human Services regulations (45 CFR \u00a746.116 and \u00a746.117) and Good Clinical Practice (ICH E6 R2). The protocols and consent forms used for the collection of human biological samples (HBS) were reviewed and approved by the ethics committee, specifically WCG IRB (IRB00000533). No animal subjects were involved in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BS, MW and JEE are current UCB employees and have equity ownership. JY and EK are former employees at UCB and have no disclosures. MHM is the CEO and founder and a shareholder of Ananda Devices Inc. The NeuroMuscle\u2122 platform is protected under the patent US 18\/939,478, owned by Ananda Devices Inc. CES and DDV are former employees at UCB and have equity ownership. The study was funded by UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}